

Paroxetine Adult Suicidality Analysis  
 Major Depressive Disorder, Short Term Trials  
 Table 1.01. Demographic Characteristics by Trial

Trial	Treatment	N	-----Age-----					-----Gender-----		-Baseline Suicidal Ideation-	
			Mean	Standard Deviation	Median	Minimum	Maximum	Males	Females	Present	Absent
Overall	PAROXETINE	3455	46.0	15.57	44.0	18	91	1424 ( 41.2%)	2031 ( 58.8%)	413 ( 12.0%)	3042 ( 88.0%)
	PLACEBO	1978	46.5	15.50	44.0	18	87	788 ( 39.8%)	1190 ( 60.2%)	240 ( 12.1%)	1736 ( 87.8%)
276	PAROXETINE	20	45.1	12.75	46.0	22	62	9 ( 45.0%)	11 ( 55.0%)	5 ( 25.0%)	15 ( 75.0%)
	PLACEBO	21	43.4	12.68	43.0	22	64	9 ( 42.9%)	12 ( 57.1%)	5 ( 23.8%)	16 ( 76.2%)
279	PAROXETINE	21	40.8	18.32	38.0	20	75	6 ( 28.6%)	15 ( 71.4%)	6 ( 28.6%)	15 ( 71.4%)
	PLACEBO	10	51.6	17.25	56.5	23	71	3 ( 30.0%)	7 ( 70.0%)	2 ( 20.0%)	8 ( 80.0%)
274	PAROXETINE	22	41.6	13.20	42.0	18	64	6 ( 27.3%)	16 ( 72.7%)	0 ( 0.0%)	22 (100.0%)
	PLACEBO	23	43.3	11.84	45.0	22	60	7 ( 30.4%)	16 ( 69.6%)	0 ( 0.0%)	23 (100.0%)
001	PAROXETINE	25	42.6	11.70	42.0	20	65	16 ( 64.0%)	9 ( 36.0%)	2 ( 8.0%)	23 ( 92.0%)
	PLACEBO	25	44.2	13.13	43.0	24	64	19 ( 76.0%)	6 ( 24.0%)	7 ( 28.0%)	18 ( 72.0%)
002	PAROXETINE	170	40.5	11.59	39.5	18	77	86 ( 50.6%)	84 ( 49.4%)	55 ( 32.4%)	115 ( 67.6%)
	PLACEBO	171	42.5	12.67	40.0	18	73	78 ( 45.6%)	93 ( 54.4%)	49 ( 28.7%)	122 ( 71.3%)
009	PAROXETINE	421	41.1	13.17	38.0	18	85	208 ( 49.4%)	213 ( 50.6%)	79 ( 18.8%)	342 ( 81.2%)
	PLACEBO	53	40.6	10.45	39.0	23	70	24 ( 45.3%)	29 ( 54.7%)	13 ( 24.5%)	40 ( 75.5%)
003	PAROXETINE	241	40.3	11.28	39.0	18	69	113 ( 46.9%)	128 ( 53.1%)	60 ( 24.9%)	181 ( 75.1%)
	PLACEBO	244	40.4	11.92	38.0	19	70	122 ( 50.0%)	122 ( 50.0%)	67 ( 27.5%)	177 ( 72.5%)
115	PAROXETINE	283	41.8	12.53	41.0	18	86	101 ( 35.7%)	182 ( 64.3%)	31 ( 11.0%)	252 ( 89.0%)
	PLACEBO	117	41.5	11.67	40.0	19	71	32 ( 27.4%)	85 ( 72.6%)	14 ( 12.0%)	103 ( 88.0%)
128	PAROXETINE	357	41.8	12.70	40.0	18	82	135 ( 37.8%)	222 ( 62.2%)	48 ( 13.4%)	309 ( 86.6%)
	PLACEBO	140	42.8	12.17	42.0	20	76	40 ( 28.6%)	100 ( 71.4%)	11 ( 7.9%)	129 ( 92.1%)
251	PAROXETINE	125	41.3	11.17	41.0	19	65	42 ( 33.6%)	83 ( 66.4%)	0 ( 0.0%)	125 (100.0%)
	PLACEBO	129	41.3	10.56	41.0	18	71	45 ( 34.9%)	84 ( 65.1%)	3 ( 2.3%)	126 ( 97.7%)
448	PAROXETINE	212	39.3	10.66	39.5	18	62	81 ( 38.2%)	131 ( 61.8%)	16 ( 7.5%)	196 ( 92.5%)
	PLACEBO	103	38.4	10.04	39.0	19	64	36 ( 35.0%)	67 ( 65.0%)	4 ( 3.9%)	99 ( 96.1%)
449	PAROXETINE	223	41.3	11.60	42.0	18	71	65 ( 29.1%)	158 ( 70.9%)	30 ( 13.5%)	193 ( 86.5%)
	PLACEBO	110	40.7	11.56	40.0	19	63	44 ( 40.0%)	66 ( 60.0%)	21 ( 19.1%)	89 ( 80.9%)
487	PAROXETINE	214	70.2	6.32	70.0	60	88	100 ( 46.7%)	114 ( 53.3%)	11 ( 5.1%)	203 ( 94.9%)
	PLACEBO	109	69.4	5.40	70.0	60	82	40 ( 36.7%)	69 ( 63.3%)	5 ( 4.6%)	104 ( 95.4%)
625	PAROXETINE	112	64.3	11.39	67.0	22	85	61 ( 54.5%)	51 ( 45.5%)	15 ( 13.4%)	97 ( 86.6%)
	PLACEBO	117	65.6	10.51	67.0	38	82	64 ( 54.7%)	53 ( 45.3%)	14 ( 12.0%)	103 ( 88.0%)
442	PAROXETINE	41	46.9	11.81	48.0	21	69	6 ( 14.6%)	35 ( 85.4%)	0 ( 0.0%)	41 (100.0%)

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation

Paroxetine Adult Suicidality Analysis  
 Major Depressive Disorder, Short Term Trials  
 Table 1.01. Demographic Characteristics by Trial

Trial	Treatment	N	-----Age-----					-----Gender-----		-Baseline Suicidal Ideation-	
			Mean	Standard Deviation	Median	Minimum	Maximum	Males	Females	Present	Absent
442	PLACEBO	48	49.0	11.49	48.0	31	79	2 ( 4.2%)	46 ( 95.8%)	0 ( 0.0%)	46 ( 95.8%)
785	PAROXETINE	197	41.3	12.19	43.0	18	65	76 ( 38.6%)	121 ( 61.4%)	46 ( 23.4%)	151 ( 76.6%)
	PLACEBO	105	40.4	11.36	40.0	18	63	46 ( 43.8%)	59 ( 56.2%)	22 ( 21.0%)	83 ( 79.0%)
810	PAROXETINE	306	38.9	11.53	38.0	18	74	131 ( 42.8%)	175 ( 57.2%)	3 ( 1.0%)	303 ( 99.0%)
	PLACEBO	148	38.5	11.78	37.0	18	65	57 ( 38.5%)	91 ( 61.5%)	2 ( 1.4%)	146 ( 98.6%)
NKD20006	PAROXETINE	124	38.0	11.85	38.5	18	64	46 ( 37.1%)	78 ( 62.9%)	0 ( 0.0%)	124 (100.0%)
	PLACEBO	125	37.7	11.20	37.0	18	63	53 ( 42.4%)	72 ( 57.6%)	0 ( 0.0%)	125 (100.0%)
874	PAROXETINE	341	67.1	6.36	66.0	60	91	136 ( 39.9%)	205 ( 60.1%)	6 ( 1.8%)	335 ( 98.2%)
	PLACEBO	180	68.0	6.73	66.0	60	87	67 ( 37.2%)	113 ( 62.8%)	1 ( 0.6%)	179 ( 99.4%)

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation

Paroxetine Adult Suicidality Analysis

Table 2.01

Number and Percent of Subjects with Definitive Suicidal Behaviour and Ideation by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	31/3455 ( 0.90%)	11/1978 ( 0.56%)	1.3 (0.7, 2.8)	0.493	(527.4)
Overall (Mantel Haenszel)	31/3455 ( 0.90%)	11/1978 ( 0.56%)	1.1 (0.6, 2.1)	0.709	(1437.4)
Trial 276	0/ 20 ( 0.00%)	0/ 21 ( 0.00%)	Not Enough Events		
Trial 279	2/ 21 ( 9.52%)	1/ 10 (10.00%)	0.9 (0.1, 30.9)		210.0
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	1/ 170 ( 0.59%)	2/ 171 ( 1.17%)	0.5 (0.0, 6.6)		172.0
Trial 009	5/ 421 ( 1.19%)	0/ 53 ( 0.00%)	inf (0.2, inf)		(84.2)
Trial 003	0/ 241 ( 0.00%)	2/ 244 ( 0.82%)	0.0 ( 0.0, 3.5)		122.0
Trial 115	5/ 283 ( 1.77%)	3/ 117 ( 2.56%)	0.7 (0.2, 3.5)		125.4
Trial 128	8/ 357 ( 2.24%)	2/ 140 ( 1.43%)	1.6 (0.4, 11.0)		(123.1)
Trial 251	2/ 125 ( 1.60%)	0/ 129 ( 0.00%)	inf (0.3, inf)		(62.5)
Trial 448	3/ 212 ( 1.42%)	0/ 103 ( 0.00%)	inf (0.3, inf)		(70.7)
Trial 449	1/ 223 ( 0.45%)	0/ 110 ( 0.00%)	inf (0.0, inf)		(223.0)
Trial 487	2/ 214 ( 0.93%)	0/ 109 ( 0.00%)	inf (0.1, inf)		(107.0)
Trial 625	1/ 112 ( 0.89%)	0/ 117 ( 0.00%)	inf (0.1, inf)		(112.0)
Trial 442	0/ 41 ( 0.00%)	0/ 48 ( 0.00%)	Not Enough Events		
Trial 785	1/ 197 ( 0.51%)	0/ 105 ( 0.00%)	inf (0.0, inf)		(197.0)
Trial 810	0/ 306 ( 0.00%)	1/ 148 ( 0.68%)	0.0 ( 0.0, 9.2)		148.0
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	0/ 341 ( 0.00%)	0/ 180 ( 0.00%)	Not Enough Events		

\*Zelen's test of homogeneity, p=0.566

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Paroxetine Adult Suicidality Analysis

Table 2.02

Number and Percent of Subjects with Rating Scale Emergent Suicidal Behaviour and Ideation by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	37/3414 ( 1.08%)	32/1930 ( 1.66%)	0.6 (0.4, 1.0)	0.050	154.3
Overall (Mantel Haenszel)	37/3414 ( 1.08%)	32/1930 ( 1.66%)	0.6 (0.4, 1.0)	0.035	152.4
Trial 276	1/ 20 ( 5.00%)	0/ 21 ( 0.00%)	inf (0.1, inf)		(20.0)
Trial 279	0/ 21 ( 0.00%)	1/ 10 (10.00%)	0.0 ( 0.0, 9.0)		10.0
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	1/ 170 ( 0.59%)	4/ 171 ( 2.34%)	0.2 (0.0, 2.0)		57.1
Trial 009	6/ 421 ( 1.43%)	1/ 53 ( 1.89%)	0.8 (0.1, 17.7)		216.6
Trial 003	3/ 241 ( 1.24%)	7/ 244 ( 2.87%)	0.4 (0.1, 1.6)		61.6
Trial 115	5/ 283 ( 1.77%)	0/ 117 ( 0.00%)	inf (0.5, inf)		(56.6)
Trial 128	6/ 357 ( 1.68%)	5/ 140 ( 3.57%)	0.5 (0.1, 1.7)		52.9
Trial 251	2/ 125 ( 1.60%)	1/ 129 ( 0.78%)	2.1 (0.2, 61.8)		(121.2)
Trial 448	0/ 212 ( 0.00%)	1/ 103 ( 0.97%)	0.0 ( 0.0, 9.2)		103.0
Trial 449	6/ 223 ( 2.69%)	3/ 110 ( 2.73%)	1.0 (0.2, 4.9)		2725.6
Trial 487	2/ 214 ( 0.93%)	1/ 109 ( 0.92%)	1.0 (0.1, 30.3)		(5831.5)
Trial 625	1/ 112 ( 0.89%)	1/ 117 ( 0.85%)	1.0 (0.0, 41.1)		(2620.8)
Trial 785	3/ 197 ( 1.52%)	4/ 105 ( 3.81%)	0.4 (0.1, 1.9)		43.7
Trial 810	0/ 306 ( 0.00%)	2/ 148 ( 1.35%)	0.0 ( 0.0, 1.7)		74.0
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	1/ 341 ( 0.29%)	1/ 180 ( 0.56%)	0.5 (0.0, 20.6)		381.2

\*Zelen's test of homogeneity, p=0.461

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

NOTE: Rating Scale Emergent Suicidal Behaviour and Ideation data was not available in Study 442

Paroxetine Adult Suicidality Analysis

Table 2.03

Number and Percent of Subjects with Composite Suicidal Behaviour and Ideation by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	62/3414 ( 1.82%)	40/1930 ( 2.07%)	0.8 (0.5, 1.2)	0.275	226.2
Overall (Mantel Haenszel)	62/3414 ( 1.82%)	40/1930 ( 2.07%)	0.8 (0.5, 1.2)	0.241	223.5
Trial 276	1/ 20 ( 5.00%)	0/ 21 ( 0.00%)	inf (0.1, inf)		(20.0)
Trial 279	2/ 21 ( 9.52%)	2/ 10 (20.00%)	0.4 (0.0, 4.8)		9.5
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	2/ 170 ( 1.18%)	6/ 171 ( 3.51%)	0.3 (0.0, 1.6)		42.9
Trial 009	10/ 421 ( 2.38%)	1/ 53 ( 1.89%)	1.3 (0.2, 28.2)		(204.7)
Trial 003	3/ 241 ( 1.24%)	7/ 244 ( 2.87%)	0.4 (0.1, 1.6)		61.6
Trial 115	7/ 283 ( 2.47%)	3/ 117 ( 2.56%)	1.0 (0.2, 4.7)		1103.7
Trial 128	14/ 357 ( 3.92%)	7/ 140 ( 5.00%)	0.8 (0.3, 2.1)		92.7
Trial 251	4/ 125 ( 3.20%)	1/ 129 ( 0.78%)	4.2 (0.5, 105.5)		(41.2)
Trial 448	3/ 212 ( 1.42%)	1/ 103 ( 0.97%)	1.5 (0.2, 38.9)		(225.1)
Trial 449	6/ 223 ( 2.69%)	3/ 110 ( 2.73%)	1.0 (0.2, 4.9)		2725.6
Trial 487	4/ 214 ( 1.87%)	1/ 109 ( 0.92%)	2.1 (0.3, 51.3)		(105.1)
Trial 625	2/ 112 ( 1.79%)	1/ 117 ( 0.85%)	2.1 (0.2, 62.7)		(107.4)
Trial 785	3/ 197 ( 1.52%)	4/ 105 ( 3.81%)	0.4 (0.1, 1.9)		43.7
Trial 810	0/ 306 ( 0.00%)	2/ 148 ( 1.35%)	0.0 ( 0.0, 1.7)		74.0
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	1/ 341 ( 0.29%)	1/ 180 ( 0.56%)	0.5 (0.0, 20.6)		381.2

\*Zelen's test of homogeneity, p=0.604

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

NOTE: Composite Suicidal Behaviour and Ideation data was not available in Study 442

Paroxetine Adult Suicidality Analysis  
 Table 2.04  
 Number and Percent of Subjects with Definitive Suicidal Behaviour by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	11/3455 ( 0.32%)	1/1978 ( 0.05%)	6.7 (1.1, 149.4)	0.058	(345.2)
Overall (Mantel Haenszel)	11/3455 ( 0.32%)	1/1978 ( 0.05%)	1.6 (0.6, 4.2)	0.363	(3515.9)
Trial 276	0/ 20 ( 0.00%)	0/ 21 ( 0.00%)	Not Enough Events		
Trial 279	1/ 21 ( 4.76%)	0/ 10 ( 0.00%)	inf (0.0, inf)		(21.0)
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	1/ 170 ( 0.59%)	1/ 171 ( 0.58%)	1.0 (0.0, 39.4)		(29070.0)
Trial 009	1/ 421 ( 0.24%)	0/ 53 ( 0.00%)	inf (0.0, inf)		(421.0)
Trial 003	0/ 241 ( 0.00%)	0/ 244 ( 0.00%)	Not Enough Events		
Trial 115	1/ 283 ( 0.35%)	0/ 117 ( 0.00%)	inf (0.0, inf)		(283.0)
Trial 128	1/ 357 ( 0.28%)	0/ 140 ( 0.00%)	inf (0.0, inf)		(357.0)
Trial 251	1/ 125 ( 0.80%)	0/ 129 ( 0.00%)	inf (0.1, inf)		(125.0)
Trial 448	2/ 212 ( 0.94%)	0/ 103 ( 0.00%)	inf (0.1, inf)		(106.0)
Trial 449	1/ 223 ( 0.45%)	0/ 110 ( 0.00%)	inf (0.0, inf)		(223.0)
Trial 487	0/ 214 ( 0.00%)	0/ 109 ( 0.00%)	Not Enough Events		
Trial 625	1/ 112 ( 0.89%)	0/ 117 ( 0.00%)	inf (0.1, inf)		(112.0)
Trial 442	0/ 41 ( 0.00%)	0/ 48 ( 0.00%)	Not Enough Events		
Trial 785	1/ 197 ( 0.51%)	0/ 105 ( 0.00%)	inf (0.0, inf)		(197.0)
Trial 810	0/ 306 ( 0.00%)	0/ 148 ( 0.00%)	Not Enough Events		
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	0/ 341 ( 0.00%)	0/ 180 ( 0.00%)	Not Enough Events		

\*Zelen's test of homogeneity, p=1.000

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Paroxetine Adult Suicidality Analysis

Table 2.05

Number and Percent of Subjects with Rating Scale Emergent Suicidal Behaviour by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	1/3414 ( 0.03%)	0/1930 ( 0.00%)	inf ( 0.0, inf)	1.000	
Overall (Mantel Haenszel)	1/3414 ( 0.03%)	0/1930 ( 0.00%)	0.4 (0.0, 9.5)	0.542	
Trial 276	0/ 20 ( 0.00%)	0/ 21 ( 0.00%)	Not Enough Events		
Trial 279	0/ 21 ( 0.00%)	0/ 10 ( 0.00%)	Not Enough Events		
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	0/ 170 ( 0.00%)	0/ 171 ( 0.00%)	Not Enough Events		
Trial 009	1/ 421 ( 0.24%)	0/ 53 ( 0.00%)	inf (0.0, inf)		(421.0)
Trial 003	0/ 241 ( 0.00%)	0/ 244 ( 0.00%)	Not Enough Events		
Trial 115	0/ 283 ( 0.00%)	0/ 117 ( 0.00%)	Not Enough Events		
Trial 128	0/ 357 ( 0.00%)	0/ 140 ( 0.00%)	Not Enough Events		
Trial 251	0/ 125 ( 0.00%)	0/ 129 ( 0.00%)	Not Enough Events		
Trial 448	0/ 212 ( 0.00%)	0/ 103 ( 0.00%)	Not Enough Events		
Trial 449	0/ 223 ( 0.00%)	0/ 110 ( 0.00%)	Not Enough Events		
Trial 487	0/ 214 ( 0.00%)	0/ 109 ( 0.00%)	Not Enough Events		
Trial 625	0/ 112 ( 0.00%)	0/ 117 ( 0.00%)	Not Enough Events		
Trial 785	0/ 197 ( 0.00%)	0/ 105 ( 0.00%)	Not Enough Events		
Trial 810	0/ 306 ( 0.00%)	0/ 148 ( 0.00%)	Not Enough Events		
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	0/ 341 ( 0.00%)	0/ 180 ( 0.00%)	Not Enough Events		

\*Test of homogeneity not carried out due to insufficient data

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

NOTE: Rating Scale Emergent Suicidal Behaviour data was not available in Study 442

Paroxetine Adult Suicidality Analysis

Table 2.06

Number and Percent of Subjects with Composite Suicidal Behaviour by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)*	12/3414 ( 0.35%)	1/1930 ( 0.05%)	6.9 (1.1, 151.9)	0.036	(329.0)
Overall (Mantel Haenszel)	12/3414 ( 0.35%)	1/1930 ( 0.05%)	1.6 (0.6, 4.3)	0.340	(3239.3)
Trial 276	0/ 20 ( 0.00%)	0/ 21 ( 0.00%)	Not Enough Events		
Trial 279	1/ 21 ( 4.76%)	0/ 10 ( 0.00%)	inf (0.0, inf)		(21.0)
Trial 274	0/ 22 ( 0.00%)	0/ 23 ( 0.00%)	Not Enough Events		
Trial 001	0/ 25 ( 0.00%)	0/ 25 ( 0.00%)	Not Enough Events		
Trial 002	1/ 170 ( 0.59%)	1/ 171 ( 0.58%)	1.0 (0.0, 39.4)		(29070.0)
Trial 009	2/ 421 ( 0.48%)	0/ 53 ( 0.00%)	inf (0.0, inf)		(210.5)
Trial 003	0/ 241 ( 0.00%)	0/ 244 ( 0.00%)	Not Enough Events		
Trial 115	1/ 283 ( 0.35%)	0/ 117 ( 0.00%)	inf (0.0, inf)		(283.0)
Trial 128	1/ 357 ( 0.28%)	0/ 140 ( 0.00%)	inf (0.0, inf)		(357.0)
Trial 251	1/ 125 ( 0.80%)	0/ 129 ( 0.00%)	inf (0.1, inf)		(125.0)
Trial 448	2/ 212 ( 0.94%)	0/ 103 ( 0.00%)	inf (0.1, inf)		(106.0)
Trial 449	1/ 223 ( 0.45%)	0/ 110 ( 0.00%)	inf (0.0, inf)		(223.0)
Trial 487	0/ 214 ( 0.00%)	0/ 109 ( 0.00%)	Not Enough Events		
Trial 625	1/ 112 ( 0.89%)	0/ 117 ( 0.00%)	inf (0.1, inf)		(112.0)
Trial 785	1/ 197 ( 0.51%)	0/ 105 ( 0.00%)	inf (0.0, inf)		(197.0)
Trial 810	0/ 306 ( 0.00%)	0/ 148 ( 0.00%)	Not Enough Events		
Trial NKD20006	0/ 124 ( 0.00%)	0/ 125 ( 0.00%)	Not Enough Events		
Trial 874	0/ 341 ( 0.00%)	0/ 180 ( 0.00%)	Not Enough Events		

\*Zelen's test of homogeneity, p=1.000

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

NOTE: Composite Suicidal Behaviour data was not available in Study 442



Paroxetine Adult Suicidality Analysis  
 Table 2.07  
 Number and Percent of Subjects with Any Adverse Event by Indication, Treatment Group and Trial  
 Indication = MDD

Trial	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (Mantel Haenszel)	2843/3414 (83.27%)	1370/1930 (70.98%)	1.9 (1.7, 2.2)	<0.001	(8.7)
Trial 276	16/ 20 (80.00%)	13/ 21 (61.90%)	2.4 (0.6, 11.1)		(5.5)
Trial 279	20/ 21 (95.24%)	8/ 10 (80.00%)	4.7 (0.3, 154.1)		(6.6)
Trial 274	19/ 22 (86.36%)	13/ 23 (56.52%)	4.7 (1.1, 24.9)		(3.4)
Trial 001	18/ 25 (72.00%)	9/ 25 (36.00%)	4.4 (1.4, 15.6)		(2.8)
Trial 002	138/ 170 (81.18%)	99/ 171 (57.89%)	3.1 (1.9, 5.1)		(4.3)
Trial 009	327/ 421 (77.67%)	31/ 53 (58.49%)	2.5 (1.3, 4.5)		(5.2)
Trial 003	209/ 241 (86.72%)	169/ 244 (69.26%)	2.9 (1.8, 4.6)		(5.7)
Trial 115	260/ 283 (91.87%)	99/ 117 (84.62%)	2.1 (1.0, 4.0)		(13.8)
Trial 128	328/ 357 (91.88%)	116/ 140 (82.86%)	2.3 (1.3, 4.2)		(11.1)
Trial 251	105/ 125 (84.00%)	103/ 129 (79.84%)	1.3 (0.7, 2.5)		(24.1)
Trial 448	190/ 212 (89.62%)	82/ 103 (79.61%)	2.2 (1.1, 4.3)		(10.0)
Trial 449	200/ 223 (89.69%)	89/ 110 (80.91%)	2.0 (1.1, 3.9)		(11.4)
Trial 487	196/ 214 (91.59%)	95/ 109 (87.16%)	1.6 (0.7, 3.4)		(22.6)
Trial 625	43/ 112 (38.39%)	37/ 117 (31.62%)	1.3 (0.8, 2.3)		(14.8)
Trial 785	157/ 197 (79.70%)	80/ 105 (76.19%)	1.2 (0.7, 2.2)		(28.5)
Trial 810	245/ 306 (80.07%)	113/ 148 (76.35%)	1.2 (0.8, 2.0)		(26.9)
Trial NKD20006	97/ 124 (78.23%)	82/ 125 (65.60%)	1.9 (1.1, 3.3)		(7.9)
Trial 874	275/ 341 (80.65%)	132/ 180 (73.33%)	1.5 (1.0, 2.3)		(13.7)

\*Breslow-Day test of homogeneity, p=0.157

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

NOTE: Exact analyses were not possible due to the large number of events

NOTE: Adverse event data was not available in Study 442

Paroxetine Adult Suicidality Analysis  
Table 2.08

Number and Percent of Subjects with Definitive Suicidal Behaviour and Ideation by Indication, Treatment Group and Risk Factors  
Indication = MDD

Description	Subgroup	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)		31/3455 ( 0.90%)	11/1978 ( 0.56%)	1.3 (0.7, 2.8)	0.493	(527.4)
Baseline Suicidal Ideation	Missing	0/ 0	0/ 2 ( 0.00%)			
	Absent	24/3042 ( 0.79%)	7/1736 ( 0.40%)	2.0 (0.9, 4.9)		(259.3)
	Present	7/ 413 ( 1.69%)	4/ 240 ( 1.67%)	1.0 (0.3, 4.0)		(3536.2)
Age Group	18-24	5/ 230 ( 2.17%)	0/ 104 ( 0.00%)	inf ( 0.6, inf)		
	25-64	23/2713 ( 0.85%)	10/1567 ( 0.64%)	1.3 (0.6, 2.9)		(477.2)
	>=65	3/ 512 ( 0.59%)	1/ 307 ( 0.33%)	1.8 (0.2, 47.6)		(384.9)
Gender	Female	18/2031 ( 0.89%)	5/1190 ( 0.42%)	2.1 (0.8, 6.4)		(214.6)
	Male	13/1424 ( 0.91%)	6/ 788 ( 0.76%)	1.2 (0.5, 3.4)		(660.3)

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation

Note. Tests of heterogeneity for Baseline Suicidal Ideation, Age Group and Gender are 0.439, 0.810, 0.492

Paroxetine Adult Suicidality Analysis

Table 2.09

Number and Percent of Subjects with Definitive Suicidal Behaviour by Indication, Treatment Group and Risk Factors  
Indication = MDD

Description	Subgroup	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (exact, adjusted)		11/3455 ( 0.32%)	1/1978 ( 0.05%)	6.7 (1.1, 149.4)	0.058	(345.2)
Baseline Suicidal Ideation	Missing	0/ 0	0/ 2 ( 0.00%)			
	Absent	9/3042 ( 0.30%)	0/1736 ( 0.00%)	inf ( 1.4, inf)		
	Present	2/ 413 ( 0.48%)	1/ 240 ( 0.42%)	1.2 (0.1, 34.4)		(1481.9)
Age Group	18-24	3/ 230 ( 1.30%)	0/ 104 ( 0.00%)	inf ( 0.3, inf)		
	25-64	8/2713 ( 0.29%)	0/1567 ( 0.00%)	inf ( 1.3, inf)		
	>=65	0/ 512 ( 0.00%)	1/ 307 ( 0.33%)	0.0 (0.0, 11.4)		(1.0)
Gender	Female	7/2031 ( 0.34%)	1/1190 ( 0.08%)	4.1 (0.6, 93.5)		(383.9)
	Male	4/1424 ( 0.28%)	0/ 788 ( 0.00%)	inf ( 0.5, inf)		

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation

Note. Tests of heterogeneity for Baseline Suicidal Ideation, Age Group and Gender are 0.254, 0.091, 1.000

Paroxetine Adult Suicidality Analysis  
 Table 2.10  
 Subjects with Definitive Suicidal Behaviour and Ideation by Age  
 Indication = MDD

Age (years)	Paroxetine	Placebo
18	2/ 17 (11.76%)	0/ 6 ( 0.00%)
19	1/ 30 ( 3.33%)	0/ 12 ( 0.00%)
20	1/ 28 ( 3.57%)	0/ 9 ( 0.00%)
21	1/ 36 ( 2.78%)	0/ 13 ( 0.00%)
22	0/ 36 ( 0.00%)	0/ 20 ( 0.00%)
23	0/ 42 ( 0.00%)	0/ 18 ( 0.00%)
24	0/ 41 ( 0.00%)	0/ 26 ( 0.00%)
25	1/ 49 ( 2.04%)	0/ 33 ( 0.00%)
26	0/ 56 ( 0.00%)	1/ 35 ( 2.86%)
27	1/ 62 ( 1.61%)	1/ 42 ( 2.38%)
28	1/ 67 ( 1.49%)	0/ 44 ( 0.00%)
29	2/ 76 ( 2.63%)	0/ 34 ( 0.00%)
30	2/ 72 ( 2.78%)	0/ 47 ( 0.00%)
31	1/ 80 ( 1.25%)	2/ 50 ( 4.00%)
32	0/ 91 ( 0.00%)	0/ 40 ( 0.00%)
33	0/ 78 ( 0.00%)	0/ 52 ( 0.00%)
34	2/ 84 ( 2.38%)	1/ 47 ( 2.13%)
35	1/ 82 ( 1.22%)	0/ 39 ( 0.00%)
36	1/ 89 ( 1.12%)	0/ 39 ( 0.00%)
37	0/ 82 ( 0.00%)	0/ 48 ( 0.00%)
38	3/ 88 ( 3.41%)	1/ 60 ( 1.67%)
39	0/ 84 ( 0.00%)	1/ 47 ( 2.13%)
40	0/ 88 ( 0.00%)	0/ 50 ( 0.00%)
41	0/ 78 ( 0.00%)	1/ 47 ( 2.13%)
42	1/ 68 ( 1.47%)	0/ 54 ( 0.00%)

Paroxetine Adult Suicidality Analysis  
 Table 2.10  
 Subjects with Definitive Suicidal Behaviour and Ideation by Age  
 Indication = MDD

Age (years)	Paroxetine	Placebo
43	0/ 87 ( 0.00%)	0/ 48 ( 0.00%)
44	0/ 82 ( 0.00%)	0/ 32 ( 0.00%)
45	1/ 83 ( 1.20%)	0/ 47 ( 0.00%)
46	1/ 74 ( 1.35%)	0/ 40 ( 0.00%)
47	0/ 68 ( 0.00%)	0/ 35 ( 0.00%)
48	0/ 60 ( 0.00%)	0/ 46 ( 0.00%)
49	3/ 69 ( 4.35%)	1/ 33 ( 3.03%)
50	0/ 58 ( 0.00%)	0/ 43 ( 0.00%)
51	1/ 53 ( 1.89%)	0/ 26 ( 0.00%)
52	0/ 56 ( 0.00%)	0/ 36 ( 0.00%)
53	0/ 50 ( 0.00%)	0/ 29 ( 0.00%)
54	0/ 49 ( 0.00%)	0/ 32 ( 0.00%)
55	0/ 56 ( 0.00%)	0/ 29 ( 0.00%)
56	0/ 52 ( 0.00%)	0/ 27 ( 0.00%)
57	0/ 39 ( 0.00%)	0/ 21 ( 0.00%)
58	1/ 31 ( 3.23%)	0/ 27 ( 0.00%)
59	0/ 38 ( 0.00%)	0/ 24 ( 0.00%)
60	0/ 82 ( 0.00%)	1/ 49 ( 2.04%)
61	0/ 72 ( 0.00%)	0/ 42 ( 0.00%)
62	0/ 70 ( 0.00%)	0/ 32 ( 0.00%)
63	0/ 52 ( 0.00%)	0/ 33 ( 0.00%)
64	0/ 58 ( 0.00%)	0/ 28 ( 0.00%)
65	0/ 44 ( 0.00%)	0/ 30 ( 0.00%)
66	0/ 52 ( 0.00%)	0/ 21 ( 0.00%)
67	0/ 45 ( 0.00%)	1/ 27 ( 3.70%)

Paroxetine Adult Suicidality Analysis  
Table 2.10  
Subjects with Definitive Suicidal Behaviour and Ideation by Age  
Indication = MDD

Age (years)	Paroxetine	Placebo
68	0/ 42 ( 0.00%)	0/ 24 ( 0.00%)
69	0/ 38 ( 0.00%)	0/ 16 ( 0.00%)
70	0/ 36 ( 0.00%)	0/ 23 ( 0.00%)
71	0/ 40 ( 0.00%)	0/ 26 ( 0.00%)
72	1/ 40 ( 2.50%)	0/ 17 ( 0.00%)
73	0/ 28 ( 0.00%)	0/ 18 ( 0.00%)
74	0/ 22 ( 0.00%)	0/ 17 ( 0.00%)
75	1/ 19 ( 5.26%)	0/ 17 ( 0.00%)
76	0/ 17 ( 0.00%)	0/ 17 ( 0.00%)
77	0/ 18 ( 0.00%)	0/ 10 ( 0.00%)
78	0/ 18 ( 0.00%)	0/ 16 ( 0.00%)
79	0/ 10 ( 0.00%)	0/ 9 ( 0.00%)
80	0/ 7 ( 0.00%)	0/ 6 ( 0.00%)
81	0/ 3 ( 0.00%)	0/ 4 ( 0.00%)
82	1/ 8 (12.50%)	0/ 5 ( 0.00%)
83	0/ 6 ( 0.00%)	0/ 1 ( 0.00%)
84	0/ 7 ( 0.00%)	0/ 1 ( 0.00%)
85	0/ 3 ( 0.00%)	0/ 0
86	0/ 4 ( 0.00%)	0/ 1 ( 0.00%)
87	0/ 1 ( 0.00%)	0/ 1 ( 0.00%)
88	0/ 3 ( 0.00%)	0/ 0
89	0/ 0	0/ 0
90	0/ 0	0/ 0
91	0/ 1 ( 0.00%)	0/ 0

Paroxetine Adult Suicidality Analysis

Table 2.11

Subjects with Either Definitive Suicidal Behaviour or Rating Scale Emergent Suicidal Behaviour  
Indication = MDD

Subject ID	Study Number	Randomized Treatment	Age (years)	Gender	Baseline Suicidal Ideation	Definitive Suicidal Behaviour	Rating Scale Emergent Suicidal Behaviour
02.001.009	002	PLACEBO	67	Female	Yes	Yes	No
02.004.089	002	PAROXETINE	19	Female	No	Yes	No
09.01A.006	009	PAROXETINE	35	Male	No	No	Yes
09.01E.260	009	PAROXETINE	51	Female	No	Yes	No
1 12 037	279	PAROXETINE	20	Male	Yes	Yes	No
115.003.0062	115	PAROXETINE	29	Female	No	Yes	No
128.001.0759	128	PAROXETINE	30	Male	No	Yes	No
251.002.0285	251	PAROXETINE	30	Male	No	Yes	No
448.010.00044	448	PAROXETINE	25	Female	No	Yes	No
448.019.00391	448	PAROXETINE	27	Female	No	Yes	No
449.021.00788	449	PAROXETINE	18	Female	No	Yes	No
625.500.02062	625	PAROXETINE	49	Male	Yes	Yes	No
785.720.00695	785	PAROXETINE	34	Female	No	Yes	No

Paroxetine Adult Suicidality Analysis  
Table 3.01  
Change from Baseline on HAMD Total Score to LOCF Endpoint by Treatment Group  
Indication = MDD

Population	Category	N	Paroxetine	Placebo	Estimated	95% CI	P-value
			LS mean	LS mean	Treatment Effect		
Overall		4609	-10.9	-8.4	-2.5	( -3.0, -2.1)	<0.001
Baseline Suicidal Ideation	Missing	2	.	.	.		
	Absent	4090	-10.9	-8.5	-2.5	( -2.9, -2.0)	
	Present	517	-11.1	-8.0	-3.1	( -4.7, -1.5)	
Age Group	18-24	282	-10.8	-9.9	-0.9	( -2.8, 0.9)	
	25-64	3671	-10.9	-8.2	-2.7	( -3.2, -2.1)	
	>=65	656	-11.3	-8.8	-2.5	( -3.7, -1.4)	
Gender	Female	2745	-11.5	-8.5	-3.0	( -3.6, -2.4)	
	Male	1864	-10.1	-8.3	-1.8	( -2.6, -1.1)	

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation



Paroxetine Adult Suicidality Analysis  
 Table 3.02  
 Change from Baseline on MADRS Total Score to LOCF Endpoint by Treatment Group  
 Indication = MDD

Population	Category	N	Paroxetine	Placebo	Estimated	95% CI	P-value
			LS mean	LS mean	Treatment Effect		
Overall		1759	-12.2	-8.5	-3.7	( -4.7, -2.7)	<0.001
Baseline Suicidal Ideation	Absent	1361	-11.8	-8.0	-3.8	( -4.9, -2.7)	
	Present	398	-13.7	-10.4	-3.2	( -5.6, -0.8)	
Age Group	18-24	105	-11.9	-8.9	-3.1	( -7.7, 1.6)	
	25-64	1479	-12.2	-8.3	-3.9	( -5.0, -2.8)	
	>=65	175	-12.1	-9.8	-2.3	( -5.2, 0.5)	
Gender	Female	903	-12.7	-8.5	-4.3	( -5.7, -2.9)	
	Male	856	-11.6	-8.6	-3.0	( -4.4, -1.6)	

Paroxetine Adult Suicidality Analysis  
 Table 3.03  
 Change from Baseline on HAMD Item 3 to LOCF Endpoint by Treatment Group  
 Indication = MDD

Population	Category	N	Paroxetine	Placebo	Estimated	95% CI	P-value
			LS mean	LS mean	Treatment Effect		
Overall		4524	-0.6	-0.5	-0.2	( -0.2, -0.1)	<0.001
Baseline Suicidal Ideation	Absent	4007	-0.5	-0.4	-0.2	( -0.2, -0.1)	
	Present	517	-1.4	-1.0	-0.4	( -0.6, -0.2)	
Age Group	18-24	281	-0.7	-0.7	0.0	( -0.1, 0.2)	
	25-64	3595	-0.6	-0.4	-0.2	( -0.2, -0.2)	
	>=65	648	-0.5	-0.4	-0.1	( -0.2, -0.1)	
Gender	Female	2668	-0.7	-0.5	-0.2	( -0.2, -0.1)	
	Male	1856	-0.6	-0.4	-0.2	( -0.3, -0.1)	

Note. Baseline HAMD Item 3 Scores were not available in study 442

Paroxetine Adult Suicidality Analysis  
Table 3.04  
Change from Baseline on MADRS Item 10 to LOCF Endpoint by Treatment Group  
Indication = MDD

Population	Category	N	Paroxetine	Placebo	Estimated	95% CI	P-value
			LS mean	LS mean	Treatment Effect		
Overall		1759	-0.9	-0.6	-0.3	( -0.4, -0.2)	<0.001
Baseline Suicidal Ideation	Absent	1361	-0.6	-0.3	-0.3	( -0.4, -0.2)	
	Present	398	-1.9	-1.4	-0.5	( -0.8, -0.3)	
Age Group	18-24	105	-0.9	-0.4	-0.5	( -1.0, -0.1)	
	25-64	1479	-1.0	-0.6	-0.3	( -0.5, -0.2)	
	>=65	175	-0.7	-0.4	-0.3	( -0.5, -0.0)	
Gender	Female	903	-0.9	-0.5	-0.4	( -0.5, -0.3)	
	Male	856	-0.9	-0.6	-0.3	( -0.4, -0.1)	

Paroxetine Adult Suicidality Analysis

Table 3.05

Number and Percent of Subjects with Declining Suicidal Ideation by Indication, Treatment Group and Risk Factors  
Indication = MDD

Description	Subgroup	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (Mantel Haenszel)		263/ 413 (63.68%)	121/ 240 (50.42%)	1.7 (1.2, 2.4)	0.002	7.6
Age Group	18-24	18/ 28 (64.29%)	10/ 19 (52.63%)	1.6 (0.5, 5.3)		8.6
	25-64	223/ 359 (62.12%)	104/ 206 (50.49%)	1.6 (1.1, 2.3)		8.6
	>=65	22/ 26 (84.62%)	7/ 15 (46.67%)	6.3 (1.4, 27.4)		2.6
Gender	Female	154/ 237 (64.98%)	71/ 129 (55.04%)	1.5 (1.0, 2.3)		10.1
	Male	109/ 176 (61.93%)	50/ 111 (45.05%)	2.0 (1.2, 3.2)		5.9

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Note. Declining Suicidal Ideation was not assessable in study 442

Note. Tests of heterogeneity for Age Group and Gender are 0.355, 0.895

Paroxetine Adult Suicidality Analysis

Table 3.06

Number and Percent of Subjects with >=50% Reduction in HAMD or MADRS Baseline Score by Indication, Treatment Group and Risk Factors  
Indication = MDD

Description	Subgroup	Paroxetine	Placebo	OR (95% CI)	P-value	NNT
Overall (Mantel Haenszel)		1688/3227 (52.31%)	702/1890 (37.14%)	1.8 (1.6, 2.0)	<0.001	7.2
Baseline Suicidal Ideation	Missing	0/ 0	0/ 2 ( 0.00%)	Not Enough Events		
	Absent	1500/2843 (52.76%)	625/1661 (37.63%)	1.9 (1.6, 2.1)		6.6
	Present	188/ 384 (48.96%)	77/ 227 (33.92%)	1.9 (1.3, 2.6)		6.6
Age Group	18-24	102/ 214 (47.66%)	45/ 98 (45.92%)	1.1 (0.7, 1.7)		57.3
	25-64	1317/2525 (52.16%)	538/1497 (35.94%)	1.9 (1.7, 2.2)		6.2
	>=65	269/ 488 (55.12%)	119/ 295 (40.34%)	1.8 (1.4, 2.5)		6.8
Gender	Female	1022/1887 (54.16%)	424/1129 (37.56%)	2.0 (1.7, 2.3)		6.0
	Male	666/1340 (49.70%)	278/ 761 (36.53%)	1.7 (1.4, 2.1)		7.6

Note. NNT numbers in brackets denote number-needed-to-harm (NNH)

Note. For two subjects in study 442 it was not possible to assess baseline suicidal ideation

Note. Tests of heterogeneity for Baseline Suicidal Ideation, Age Group and Gender are 0.960, 0.062, 0.264